"10.1371_journal.pone.0105434","plos one","2014-08-22T00:00:00Z","Simone C Wuest; Ina Mexhitaj; Noo Ri Chai; Elena Romm; Joerg Scheffel; Biying Xu; Kelly Lane; Tianxia Wu; Bibiana Bielekova","Neuroimmunological Diseases Unit, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America; Molecular Immunology Section, Laboratory of Molecular Immunogenetics, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, United States of America; Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States of America; Clinical Neurosciences Program, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America","Conceived and designed the experiments: SCW BB. Performed the experiments: SCW IM NRC ER JS BX KL. Analyzed the data: TW. Contributed reagents/materials/analysis tools: JS. Contributed to the writing of the manuscript: SCW BB.","Bibiana Bielekova, MD, is a co-inventor on NIH patents related to daclizumab therapy and as such has received royalty payments based upon license to US patents 7,575,742 and 7,258,859 (and patent applications claiming priority to these patents) and other National Stage patents and patent applications claiming priority to PCT/US2002/038290 or PCT/US2003/020428. The clinical trial aspect of the study has been partially supported by a collaborative research agreement between the NINDS and Biogen/Abbott (CRADA# 2010-0039). The other authors have no competing interests to report. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.","2014","08","Simone C Wuest","SCW",9,FALSE,2,7,1,NA,TRUE,FALSE,FALSE,0,NA,FALSE
